Industry
Biotechnology
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of solid tumors; and phase 1B clinical trial to treat COVID-19. It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat solid tumors, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California.
Loading...
Open
1.38
Mkt cap
258M
Volume
1.7M
High
1.43
P/E Ratio
-1.56
52-wk high
1.93
Low
1.36
Div yield
N/A
52-wk low
0.41
Portfolio Pulse from
November 07, 2024 | 9:30 pm
Portfolio Pulse from
November 06, 2024 | 11:15 pm
Portfolio Pulse from Benzinga Newsdesk
October 29, 2024 | 1:12 pm
Portfolio Pulse from Benzinga Newsdesk
October 29, 2024 | 1:09 pm
Portfolio Pulse from Benzinga Newsdesk
October 17, 2024 | 4:10 pm
Portfolio Pulse from Benzinga Newsdesk
September 30, 2024 | 2:56 pm
Portfolio Pulse from Benzinga Newsdesk
September 25, 2024 | 7:34 am
Portfolio Pulse from Benzinga Newsdesk
August 08, 2024 | 9:41 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.